Interstitial magnetic resonance lymphography with gadobutrol in rats - Evaluation of contrast kinetics

被引:25
作者
Fink, C
Bock, M
Kiessling, F
Delorme, S
机构
[1] DKFZ, Abt Onkol Diagnost, Forschungsschwerpunkt Radiol Diagnost & Therapie, D-69120 Heidelberg, Germany
[2] Abt Biophys & Med Strahlenphys, Heidelberg, Germany
关键词
MR lymphography; animal studies; cancer; metastasis;
D O I
10.1097/00004424-200212000-00004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
RATIONALE AND OBJECTIVE. To evaluate the contrast kinetics of gadobutrol for interstitial MR lymphography. MATERIALS AND METHODS. In 11 rats, 0.5 mL undiluted gadobutrol was injected subcutaneously into the hind paw. Contrast kinetics were measured in lymph nodes, kidney, liver, muscle, and blood of six animals using a time-resolved 2D GRE sequence. Additionally, high-resolution 3D T1-weighted data sets were obtained in five animals. RESULTS. Immediately after injection, a pronounced signal intensity loss was observed in popliteal, inguinal and aortoiliac lymph nodes, followed by a continuous signal intensity increase. From the data peak concentrations of up to 78 mmol/L were estimated for selected lymph nodes. A contrast enhancement was also observed in kidneys, liver, muscle, and blood. Regional lymphatic vessels, the thoracic duct, as well as popliteal, inguinal, aorto-iliac, and axillary lymph node groups could be visualized with the high-resolution 3D MRI. CONCLUSION. Gadobutrol is suitable for interstitial MR lymphography, as it rapidly appears in the lymphatic system. Based on estimates of local tissue concentrations future studies have to assess the optimal contrast agent dosage. Furthermore, the investigation of metastatic lymph nodes is required to evaluate the further potential of gadobutrol for interstitial MR lymphography.
引用
收藏
页码:655 / 662
页数:8
相关论文
共 30 条
[1]  
ANZAI Y, 1994, AM J NEURORADIOL, V15, P87
[2]   Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience [J].
Bellin, MF ;
Roy, C ;
Kinkel, K ;
Thoumas, D ;
Zaim, S ;
Vanel, D ;
Tuchmann, C ;
Richard, F ;
Jacqmin, D ;
Delcourt, A ;
Challier, E ;
Lebret, T ;
Cluzel, P .
RADIOLOGY, 1998, 207 (03) :799-808
[3]   Comparison of CT and MR imaging in staging of neck metastases [J].
Curtin, HD ;
Ishwaran, H ;
Mancuso, AA ;
Dalley, RW ;
Caudry, DJ ;
McNeil, BJ .
RADIOLOGY, 1998, 207 (01) :123-130
[4]   NMR RELAXATION-TIMES OF BLOOD - DEPENDENCE ON FIELD-STRENGTH, OXIDATION-STATE, AND CELL INTEGRITY [J].
GOMORI, JM ;
GROSSMAN, RI ;
YUIP, C ;
ASAKURA, T .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1987, 11 (04) :684-690
[5]   0.5 M Gd chelate (Magnevist®) versus 1.0 M Gd chelate (Gadovist®):: Dose-independent effect on image quality of pelvic three-dimensional MR-angiography [J].
Goyen, M ;
Lauenstein, TC ;
Herborn, CU ;
Debatin, JF ;
Bosk, S ;
Ruehm, SG .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2001, 14 (05) :602-607
[6]   MR LYMPHOGRAPHY WITH IRON-OXIDE PARTICLES - DOSE-RESPONSE STUDIES AND PULSE SEQUENCE OPTIMIZATION IN RABBITS [J].
HAMM, B ;
TAUPITZ, M ;
HUSSMANN, P ;
WAGNER, S ;
WOLF, KJ .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1992, 158 (01) :183-190
[7]   Macromolecular intravenous contrast agent for MR lymphography: Characterization and efficacy studies [J].
Harika, L ;
Weissleder, R ;
Poss, K ;
Papisov, MI .
RADIOLOGY, 1996, 198 (02) :365-370
[8]   MR LYMPHOGRAPHY WITH A LYMPHOTROPIC T-1-TYPE MR CONTRAST AGENT - GD-DTPA-PGM [J].
HARIKA, L ;
WEISSLEDER, R ;
POSS, K ;
ZIMMER, C ;
PAPISOV, MI ;
BRADY, TJ .
MAGNETIC RESONANCE IN MEDICINE, 1995, 33 (01) :88-92
[9]  
HENZE E, 1982, J NUCL MED, V23, P923
[10]   Interstitial magnetic resonance lymphography using a polymeric T1 contrast agent - Initial experience with gadomer-17 [J].
Misselwitz, B ;
Schmitt-Willich, H ;
Michaelis, M ;
Oellinger, JJ .
INVESTIGATIVE RADIOLOGY, 2002, 37 (03) :146-151